BioAge Labs Announces $198M Initial Public Offering
September 28, 2024
September 28, 2024
PALO ALTO, California, Sept. 28 -- Cooley, a law firm, issued the following news release:
New York - September 27, 2024 - Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering (IPO).
BioAge issued and sold 11,000,000 shares priced at $18 per share, with a 30-day option for the underwrite . . .
New York - September 27, 2024 - Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering (IPO).
BioAge issued and sold 11,000,000 shares priced at $18 per share, with a 30-day option for the underwrite . . .